Supplementary Figure S3 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

(A-B) Flow cytometry assays of tumor infiltration proportions of CD11b+ F4/80+ MHC-II+ macrophages and CD3+ CD8+ PD-1+ T cells in orthotopic Hepa1-6 tumors with Slamf7 overexpression and control groups. (C) Heatmap showing the immunological activity ssGSEA scores in tumor samples from TCGA-LIHC cohort. The upper horizontal bars represent the expression level of SLAMF7. (D) Correlation matrix showing the relationships between SLAMF7 level and various immune activity scores in tumors from TCGA-LIHC cohort. (E) Violin diagrams showing the percentages of 22 immune cell types calculated using the CIBERSORT method in HCC tumors with SLAMF7 high and low expression groups. (F) The standardized risk score of a T cell exhaustion (TEX) signature between tumors with low and high SLAMF7 expression in the TCGA-LIHC cohort. (G) Correlation of the risk score of a M2-like macrophage-related gene signature with mRNA level of SLAMF7 in GSE14520 cohort. (H) Immunologic signature gene sets enriched in HCC with high SLAMF7 expression from TCGA-LIHC cohort. Student’s t test.